Taysha基因疗法公司在Rett综合征关键基因治疗项目Tsha-102取得重要进展

美股速递
Jan 06

Taysha基因疗法公司宣布,其针对Rett综合征研发的核心基因治疗候选药物Tsha-102在关键项目推进中取得显著进展。该项目的阶段性成果标志着公司在神经系统疾病基因治疗领域迈出坚实一步,为罕见病治疗带来新的希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10